In summary, since its discovery as an oncogene, MET has been found to undergo mutations, amplifications, or rearrangements in a wide range of cancers, spanning from the early stages of tumor initiation to instances of therapeutic resistance and recurrence. The gene discussed is MET; the disease is cancer.